Skip to main content

Table 1 Inclusion criteria based on the PICOS format for the study conducted

From: Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

PICOS Inclusion Criteria Exclusion Criteria
Participants Pediatrics including neonateswith microscopically confirmed, uncomplicated P. falciparum orVivax malaria.
With mono-infections
In-vitro studies
All with sever malaria
All with other types of malaria and co-infections/mixed infections
Interventions Treatment at least three-day course of an ACT (fixed dosed, co-blistered, or individually packaged (loose)) Prophylaxis
Studies that do not report ACT
For non-comparative trials, those with ACT and other drugs with antimalarial properties
Artemisinin mono-therapy
Comparison An ACT with or without comparative arm interventions (ACT with ACT, ACT with non-ACT, ACT alone) Studies that do not report an ACT
Outcome measures Efficacy: PCR corrected day 28 and 42 ACPR and
Safety: Adverse drug events including associated deaths
Follow-ups less than day 28
Studies All study designs globally
Published in English
No restriction to number of authors
Published until March 06, 2020
phase III/IV clinical trials
News, communication, qualitative studies, case reports
all non-published studies and published in non –English languages
Phase I/II trials.
Overall Must fulfill all above inclusion criteria’s Must not include either of the above